BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21189414)

  • 1. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I.
    Varrone A; Tóth M; Steiger C; Takano A; Guilloteau D; Ichise M; Gulyás B; Halldin C
    J Nucl Med; 2011 Jan; 52(1):132-9. PubMed ID: 21189414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter.
    Schou M; Steiger C; Varrone A; Guilloteau D; Halldin C
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4843-5. PubMed ID: 19577467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of [(18)F]beta-CFT-FE (2beta-carbomethoxy-3beta-(4-fluorophenyl)-8-(2-[(18)F]fluoroethyl)nortropane) as a dopamine transporter ligand: A PET study in the conscious monkey brain.
    Harada N; Ohba H; Fukumoto D; Kakiuchi T; Tsukada H
    Synapse; 2004 Oct; 54(1):37-45. PubMed ID: 15300883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
    Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
    J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplified quantification and whole-body distribution of [18F]FE-PE2I in nonhuman primates: prediction for human studies.
    Varrone A; Gulyás B; Takano A; Stabin MG; Jonsson C; Halldin C
    Nucl Med Biol; 2012 Feb; 39(2):295-303. PubMed ID: 22033024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of 3H-labeled N-(3-iodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(4-methylphenyl)nortropane (PE2I) and its interaction with mice striatal membrane fragments.
    Stepanov V; Schou M; Järv J; Halldin C
    Appl Radiat Isot; 2007 Mar; 65(3):293-300. PubMed ID: 17081763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.
    Ziebell M
    Dan Med Bull; 2011 May; 58(5):B4279. PubMed ID: 21535991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models.
    Seki C; Ito H; Ichimiya T; Arakawa R; Ikoma Y; Shidahara M; Maeda J; Takano A; Takahashi H; Kimura Y; Suzuki K; Kanno I; Suhara T
    Ann Nucl Med; 2010 May; 24(4):249-60. PubMed ID: 20364374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [(11)C]PE2I in healthy volunteers.
    Ribeiro MJ; Ricard M; Lièvre MA; Bourgeois S; Emond P; Gervais P; Dollé F; Syrota A
    Nucl Med Biol; 2007 May; 34(4):465-70. PubMed ID: 17499737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET.
    Saba W; Valette H; Schöllhorn-Peyronneau MA; Coulon C; Ottaviani M; Chalon S; Dolle F; Emond P; Halldin C; Helfenbein J; Madelmont JC; Deloye JB; Guilloteau D; Bottlaender M
    Synapse; 2007 Jan; 61(1):17-23. PubMed ID: 17068778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
    Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
    Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.
    Plisson C; McConathy J; Martarello L; Malveaux EJ; Camp VM; Williams L; Votaw JR; Goodman MM
    J Med Chem; 2004 Feb; 47(5):1122-35. PubMed ID: 14971892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and in vivo evaluation of fluorine-18 and iodine-123 labeled 2beta-carbo(2-fluoroethoxy)-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane as a candidate serotonin transporter imaging agent.
    Plisson C; Stehouwer JS; Voll RJ; Howell L; Votaw JR; Owens MJ; Goodman MM
    J Med Chem; 2007 Sep; 50(19):4553-60. PubMed ID: 17705359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand
    Lizana H; Johansson L; Axelsson J; Larsson A; Ögren M; Linder J; Halldin C; Varrone A; Mo SJ
    J Nucl Med; 2018 Aug; 59(8):1275-1280. PubMed ID: 29348315
    [No Abstract]   [Full Text] [Related]  

  • 19. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements.
    Zoghbi SS; Shetty HU; Ichise M; Fujita M; Imaizumi M; Liow JS; Shah J; Musachio JL; Pike VW; Innis RB
    J Nucl Med; 2006 Mar; 47(3):520-7. PubMed ID: 16513622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slow isomerization step in the interaction between mouse dopamine transporter and dopamine re-uptake inhibitor N-(3-iodoprop-2E-enyl)-2beta-carbo-[3H]methoxy-3beta-(4'-methylphenyl)nortropane.
    Stepanov V; Järv J
    Neurosci Lett; 2006 Dec; 410(3):218-21. PubMed ID: 17074440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.